$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cidara Therapeutics, Inc. (NASD... GlobeNewswire
Market data is delayed by at least 15 minutes.
    Latest Story Top Stories on CDTX
    Halper Sadeh LLC Encourages CDTX, MRSN, HOLX Shareholders to Contact the Firm to Discuss Their Rights
    3:19p ET November 14 '25 PR Newswire

    Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

    Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

    https://mma.prnewswire.com/media/1896150/Firm_Logo_with_Investor_Law_Firm_Logo.jpg

    Cidara Therapeutics, Inc. (NASDAQ: CDTX)'ssale to Merck for $221.50 per share in cash.If you are a Cidara shareholder,click here to learn more about your rights and options.

    Mersana Therapeutics, Inc. (NASDAQ: MRSN)'s sale to Day One Biopharmaceuticals, Inc. Under the terms of the proposed transaction, Mersana shareholders will receive $25.00 per share in cash plus one non-tradable contingent value right (CVR) per share to receive certain potential milestone payments of up to $30.25 per CVR in cash, for total consideration of up to $55.25 per share in cash.If you are a Mersana shareholder, click here to learn more about your legal rights and options.

    Hologic, Inc. (NASDAQ: HOLX)'ssale to funds managed by Blackstone and TPG. Under the terms of the proposed transaction, Hologic shareholders will receive $76.00 per share in cash plus a non-tradable contingent value right to receive up to $3.00 per share in two payments of up to $1.50 each.If you are a Hologic shareholder,click here to learn more about your rights and options.

    Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

    Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.comor zhalper@halpersadeh.com.

    Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

    Attorney Advertising. Prior results do not guarantee a similar outcome.

    Contact Information:Halper Sadeh LLCDaniel Sadeh, Esq.Zachary Halper, Esq.(212) 763-0060sadeh@halpersadeh.comzhalper@halpersadeh.com https://www.halpersadeh.com

    https://edge.prnewswire.com/c/img/favicon.png?sn=NY25114&sd=2025-11-14

    View original content to download multimedia:https://www.prnewswire.com/news-releases/halper-sadeh-llc-encourages-cdtx-mrsn-holx-shareholders-to-contact-the-firm-to-discuss-their-rights-302615955.html

    SOURCE Halper Sadeh LLP

    https://rt.newswire.ca/rt.gif?NewsItemId=NY25114&Transmission_Id=202511141519PR_NEWS_USPR_____NY25114&DateId=20251114

    COMTEX_470255662/1005/2025-11-14T15:19:34

    Halper Sadeh LLC Encourages CDTX, MRSN, HOLX Shareholders to Contact ...
    3:19p ET November 14 '25 PR Newswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Follow...
    10:41a ET November 14 '25 GlobeNewswire
    Shareholder Alert: The Ademi Firm investigates whether Cidara Therape...
    10:08a ET November 14 '25 PR Newswire
    Cidara Therapeutics Provides Corporate Update and Reports Third Quart...
    4:07p ET November 6 '25 GlobeNewswire
    Cidara Therapeutics to Participate in November Investor Conferences
    8:00a ET October 28 '25 GlobeNewswire
    Cidara Therapeutics to Report Third Quarter 2025 Financial Results an...
    4:05p ET October 23 '25 GlobeNewswire
    Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at ...
    8:00a ET October 23 '25 GlobeNewswire
    Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentatio...
    8:00a ET October 21 '25 GlobeNewswire
    Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on...
    8:00a ET October 13 '25 GlobeNewswire
    Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025
    8:00a ET October 10 '25 GlobeNewswire

    Market data provided by News provided by